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Review of Literature
Introduction

Prostaglandins are potent mediators of many physiologic and pathologic

processes. In humans, prostaglandins are involved in different functions such as blood
dotting, nerve and growth development, wound healing, and immune responses [ 1 ].

Inflammatory agents stimulate their production and they may mediate some effects of
inflammatory agents on bone. In particular, prostaglandins are potent stimulators ofbone
resorption [2] and may play a role in the bone loss associated with inflammation. Many
studies have shown that prostaglandins, especially PGE2, are involved in the pathogenesis

of periodontal diseases [3, 4] and associated with attachmem loss [3]. Prostaglandins
have also been shown to be involved in orthodontic tooth movement [5] [6]. This project
examines regulation of prostaglandins by inflammatory agents in bone cells.

Prostaelandin Metabolic Pathway

Prostaglandin production involves two important regulatory steps. The first step
is the release of arachidonic acid from membrane phospholipids by phospholipase A.

The second step is the conversion of arachidonic acid to PGG2 and subsequemly to PGH2

(Figure 1). Both reactions are a function of a single enzyme, prostaglandin G/H synthase

(PGHS), which acts as both a cyclooxygenase and a peroxidase. Because of its
cyclooxygenase functions, the enzyme is commonly called COX. COX is generally the
rate-limiting enzyme in the biosynthesis of prostaglandins [7]. PGH2 is converted by

specific isomerases or reductases to PGD:, PGEz, PGFz, prostacyclin (PGI:) and

thromboxane A: (TxA:) [8]. The prostanoids probably exit the cell via facilitated
diffusion [8]. Recently, two isozymes of COX have been characterized and labeled

COX-1 and COX-2. The COX-1 gene is about 22 kb long with 11 exons, while the
COX-2 gene is about 8 kb long with 10 exons [9]. Both enzymes are approximately
60% identical at amino acid and nucleic acid levels and are both about 70 kD in size.

COX-1 is constitutively expressed and is thought to be the "housekeeping" enzyme

responsible for the production of prostaglandins required to maintain physiologic

processes. COX-2 is the inducible form of cyclooxgenase. COX-2 is induced during the
inflammatory process and is thought to be largely responsible for the production of

prostaglandins involved in pathologic processes. COX-2 is expressed at undetectable
levels in most tissues but may be rapidly induced to high levels by numerous factors [7,

Reffulators of Prostaelandin Production

There are many regulators of bone metabolism that stimulate prostaglandin

production in bone. COX-2 expression is stimulated in bone by factors such as cytokines,

growth factors, and hormones. These include parathyroid hormone (PTH)[ 10],
transforming growth factors-or and -13[ 11 ], tumor necrosis factor-a[ 12], and fluid shear

stress[ 13]. In addition, prostaglandins themselves have been shown to induce COX-2
expression and increase their own production[ 14, 15]. Intedeukin-1 (IL-1) and

lipopolysaccharide (LPS) are important inflammatory factors that can stimulate

prostaglandin production by increasing the expression of COX-2 [ 14, 16]. IL-1 has been

shown to induce COX-2 expression and prostaglandin production in cultured neonatal
calvariae from mice [12] and in clonal osteoblastic MC3T3-E1 cells which were

originally derived from murine ealvariae [ 17]. LPS, a component of the membrane of
gram-negative bacteria, can induce COX-2 expression and prostaglandin production in
human gingival fibroblasts [ 18]. Inhibitors of prostaglandin production that act by

inhibiting COX-2 expression include IL-4, retinoic acid, and glueoeortieoids such as
dexamethasone [ 12, 19].
Much of the regulation of COX-2 production in bone cells is mediated at the level

of transcription of DNA into RNA [20-22]. Using osteoblastic clonal MC3T3-E 1 murine
cells transfected with plasmids carrying sections of the proximal 5’-flanking region of the
murine COX-2 gene fused to a luciferase reporter gene, the-371/+70 bp region has been

shown to be sufficient to mediate many COX-2 responses, including the response to IL-1

[20, 22]. However, the LPS stimulation of COX-2 expression and of luciferase activity
in these cells has not yet been studied.

Prostaglandins and Bone Resorption

..Effects on Osteoclast Formation
Bone is constantly undergoing the process of remodeling in which mineralized
bone is resorbed on a particular bony surface, followed by a phase of bone formation. In
normal adults, there is a coupling process so that formation follows resorption at each
local site. This concept ofbone remodeling is based on the hypothesis that bone-

resorbing cells or osteoclasts become activated and begin the process of bone resorption.

Osteodasts have a limited lifespan and undergo apoptosis. Resorption is then followed

by a quiescent reversal phase, after which the bone forming cells, appear and make new
bone matrix. A number of systemic factors such as PTH and vitamin D3, and local

factors including prostaglandins, leukotrienes, cytokines, and growth factors participate
in the bone remodeling process [23]. Many ofthese factors act on the osteoblasts, which

in turn mediate the signals for osteoclastic bone resorption.

Prostaglandins are abundant in bone cells. They are primarily produced and

regulated by osteoblasts. Osteoblasts are derived from mesenchymal or stromal stem
cells in the bone marrow. The precursor cells differentiate into preosteoblasts and then
into mature osteoblasts, which are involved in the synthesis of organic matrix

components and mineralization. Osteoblasts have receptors for many factors that

regulate bone turnover, such as PTH, IL-1, prostaglandins, estrogens and vitamin D3.

Some osteoblasts (called osteocytes) are incorporated into the mineralized matrix.

Osteocytes communicate with each other and with other bone lining cells through
cytoplasmic processes. Osteocytes may be the cells that mediate the remodeling
processes in response to mechanical loading. Cells ofthe osteoblast lineage are also
involved in the production of paracrine and autocrine factors, such as cytokines and

growth factors, which influence bone formation and bone resorption.

Osteoclasts, the bone-resorbing cells, arise from hematopoietic stem cells in the
bone marrow. The osteoclast progenitors proliferate and differentiate into mononuclear

preosteoclasts and fuse with each other to form multinucleated osteoclasts. The
formation of mature osteoclasts requires a contact-dependent interaction between

hematopoietic osteoclast progenitors and osteoblasts or other stromal cells (Figure 2)

[24]. The molecule responsible for this interaction is a membrane-bound factor that is
expressed by osteoblasts or stromal cells in response to most resorption-stimulating

factors. This molecule has been recemly identified as a receptor activator of nuclear
factor (NF)-rd3 ligand (RANKL), also found on T-cells [25], and is idemical to
osteoprotegerin ligand (OPGL) [26], TNF-related activation-induced eytokine

(TRANCE) [27], and osteoclast-differentiating factor (ODF) [25]. Osteoprotegerin
(OPG), also called osteoclastogenesis inhibitory factor (OCIF), is a soluble receptor of
the TNF receptor-ligand family and inhibits bone resorption by preventing the binding of

RANKL to its receptor RANK [25]. Osteoblastic cells also produce OPG. It was
recently reported that OPG inhibits in vitro osteoclast formation from three different
signaling pathways stimulated by 1,25(OH)D3, PTH, or IL-11 [28].
Prostaglandins have been shown to be necessary for maximal development of

osteoclasts in cultures stimulated by IL-1129], TNFct [30], PTH [31], 1, 25(OH):D3 [32],
IL-11 [33], and IL-6 [22]. Prostaglandins are thought to enhance osteoclastogenesis

largely via increasing RANKL expression and decreasing OPG expression.
Prostaglandins as well as 1,25(OH)2D3, and PTH have been shown to stimulate bone
resorption through the induction of RANKL expression in osteoblasts [34-37]. Yasuda et
al. have shown that RANKL gene expression was upregulated in osteoblasts of mice

cultured with 1,25(OH):D3, IL-11, PGE2, or PTH [34]. They also demonstrated that

OPG inhibited osteoclast formation that was elicited by the same stimulators in
cocultures of spleen cells and osteoblasts [34]. Similarly, Lacey et al. reported that in
murine bone marrow macrophages, osteoclastic differemiation was increased with
treatment of PGE before the addition of osteoblastic/stromal cells, 1,25(OH):D3, and

treatment of PGE before the addition of osteoblastic/stromal cells, 1,25(OH)2D3, and

dexamethasone [38]. Brandstrom et al. showed that PGE, in a time and dose-dependent
manner, decreased OPG mRNA levels in human bone marrow stroma cells (hBMSC)

[39]. This study also suggests that the down-regulation by PGE: is mediated via a cAMP
dependent mechanism.
Okada et al. studied tissues from COX-2 knockout mice and showed that the
prostaglandins which enhance osteoclast formation in response to PTH and 1,25 D, are

produced by COX-2 in osteoblasts [40]. They found that in marrow cultures from COX2 -deficient (-/-) mice, 1,25 D and PTH- stimulated osteoclast formation was decreased
relative to the COX-2 (+/+) mice. The decrease was reversed when PGE: was added to

the cultures. In addition, there was decreased osteoclast formation when the COX-2deficient (-/-) osteoblasts were cultured with +/+ or -/- spleen cells, but not when +/+

osteoblasts were cultured with -/- spleen cells or when PGE: was added to the cultures.

They could therefore conclude that this decreased osteoclast formation is due to the
decreased prostaglandin production by COX-2 in osteoblastic/stromal cells. These same
studies suggest that prostaglandins stimulate osteoclast formation in marrow cultures via

enhanced expression of RANKL.
Studies in spleen cell cultures in which the need for support cells is replaced by
addition of RANKL to the cultures, suggest that prostaglandins also have a direct effect
on osteoclastic precursors to enhance osteoclast formation [32, 40]. The inhibition of

GM-CSF, granulocyte macrophage- colony stimulating factor, an inhibitor of osteoclast
formation may mediate this effect, by prostaglandins [40]. The receptor, which mediates

the effects of PGE: in the spleen cultures, has been identified as the EP: receptor (Li and

Raisz, submitted to Endocrinology).

Macrophage-colony stimulating factor (M-CSF), which is produced by
osteoblastic cells, is also necessary for osteoclast development. Osteoblastic cells

produce M-CSF constitutively and increase their production in response to
proinflammatory agents [41 ]. Mice in which the M-CSF gene is not functional have
osteopetrosis, op/op mice. Takahashi et al. showed that when osteoblastic cells from

normal mice were cocultured with spleen cells (osteoclast precursors) derived from op/op
mice, osteoclasts were formed [42]. However, osteoclasts never formed in cocultures of

normal spleen cells and op/op osteoblastic cells, suggesting that the osteoclast deficiency
in these mice is due to a defect in osteoblastic cells but not in spleen cells[42]. The

impaired bone resorption in these mice was restored when given M-CSF [43]. These
results confirm that M-CSF produced by osteoblasts/stromal cells plays an essemial role
in osteoclast development. Although M-CSF has been shown to increase osteoclast

formation, prostaglandins inhibit M-CSF expression [41, 44]. Thus, the ability of
prostaglandins to increase osteoclast formation is probably not through the effects of

prostaglandins on M-CSF expression.

Prostaglandin Effects on Resorption in Organ Culture
The earliest studies by Raisz and Martin [45] showed that prostaglandins,

especially of the E series (PGE:) stimulated bone resorption in the fetal rat long bone

organ culture system through cyclic AMP production. Many factors that stimulate
prostaglandin production also stimulate resorption in organ culture. The resorption
stimulated by such factors can be mediated in part by prostaglandin production [ 11, 29,

46]. Previous studies have examined the role of prostaglandin synthesis on bone
resorption stimulated by cytokines or other factors. Gowen et al. [47] reported that IL-1
stimulates bone resorption in mouse ealvarial cultures via a prostaglandin-independent
mechanism. The addition of indomethacin, an inhibitor ofboth COX-1 and COX-2

activity, did not affect IL-l-induced bone resorption. However, another study using bone

organ culture systems found that IL-1 induced bone resorption and osteoclast formation
via a prostaglandin-dependent mechanism [29]. Dewhirst et al. also reported IL-1-

stimulated resorption in the fetal rat long bone system is blocked by indomethacin,

suggesting the involvement of prostaglandins [48]. Although results in organ culture
show variable dependence of resorption on prostaglandin production, many studies have
found prostaglandins to be necessary for maximal formation of osteoclasts, as noted
above. These findings suggest that prostaglandins may play a more important role in the

generation of new osteoclasts than in the activity of mature osteoclasts.

Boyce et a1.[49] also found both prostaglandin-dependent and prostaglandinindependent stimulation ofbone with IL-1 in vivo. They injected mice subcutaneously
above the calvaria with IL-1 for 3 days in the presence and absence of systemic
indomethacin. The indomethacin was continued after the IL-1 was stopped. During the
treatment with IL-1, stimulation of osteoclastic bone resorption was not inhibited by
treatment with indomethacin.

However, when the IL-1 treatment was stopped after 3

days, the osteoclastic resorption continued up to 27 days and was inhibited by
indomethacin [49]. This suggests that the long-term effect was mediated by

prostaglandins, consistent with the ability of prostaglandins to stimulate new osteoclast
formation.

prostaglandins and Inflammatio,,n

Although the importance of COX activity in the production of prostaglandins has
been known for many years, the induction of COX-2 and its role in inflammation has

only been appreciated recently[ 1 ]. Periodontal disease is an inflammatory disorder that
often leads to irreversible alveolar bone resorption and tooth loss. It initiates as a
bacterial infection in the gingiva and progresses to attachmem loss ofthe periodontal

ligament, which anchors teeth to the surrounding bone. Because there are minimal
systemic effects of periodontitis, it is likely that soft tissue and alveolar bone loss around
the affected teeth results from the local release of inflammatory mediators secondary to
bacterial infection [50]. The bone loss associated with periodontal disease is

hypothesized to be a result of an uncoupling of bone resorption and bone formation

processes in which local cytokines are released from inflammatory cells. The increased
bone loss is thought to reflect an increase in bone resorption compared to bone formation.

Some important inflammatory mediators in periodontal disease are PGE, IL-1, IL-6, and

TNFc [51 ]. Bone cells and resident fibroblasts and leukocytes in the inflammatory
infiltrate, especially macrophages, can produce the cytokine mediators. Inhibition of

PGE production suppresses or blocks alveolar bone destruction in both experimental
animals and periodontitis in humans [52-54]. However, the actual functions of these

major mediators in normal bone in the periodontium and bone destruction in periodontitis

needs further investigation.
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Inflammatory Mediators

Interleukin-1 (IL-!):

IL-1, one ofthe first pro-inflammatory molecules discovered, is a key mediator
of the human body’s response to microbial invasion, inflammation, autoimmune

reactions, and tissue injury [55]. There are two molecular forms of 1L-1" IL-1 a and IL-

11, which are encoded by separate genes. 1L-1 is predominantly produced by
macrophages activated by microbial substances, immune complexes or other eytokines,
or by lymphocytes. It can also be released from platelets, fibroblasts, keratinocytes, and

endothelial cells [56]. IL-1 can also induce its own production[57]. The activity oflL-1
can be suppressed by the release of a specific inhibitor protein, which serves as an IL-1

receptor antagonist (IL-lra). IL-lra binds to and occupies the IL-1 receptor, but does not
activate the cell receptor. Some ofthe IL-1 biological effects include cell proliferation,

increased collagen and collagenase synthesis, bone resorption, and PGE2 synthesis in
fibroblasts [55, 56]. As mentioned earlier, the bone resorbing activity ofIL-1 has been
studied in vitro and in vivo and some of this activity may be mediated by prostaglandins

[46, 49, 58]. IL-1 has been shown to stimulate COX-2 expression in osteoblastic cells
and neonatal murine calvaria, thereby increasing prostaglandin production [ 14, 17]. IL-1
has also induced COX-2 expression in other cell types such as human endothelial cells,
human decidual cells, and rat endometrial stromal cells [59-61 ]. Recently, Nakagawa et
al. showed that IL-1 a induces COX-2 promoter activity in a dose-dependent manner, and

promoted COX-2 mRNA expression in bone-derived endothelial cells suggesting a
possible role in bone remodeling. [62].
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Lpopolysacchardes (LPS):

LPS is one of the main bacterial components responsible for inducing proinflammatory cytokine expression, COX-2, and prostaglandin production. It is a critical
mediator of the host response in Gram-negative infections. Systemically administered

LPS is a potent toxin that can cause fever, shock, intravaseular coagulation, and death

[51 ]. LPS is a structural component of all Gram-negative bacterial cell walls, and
consists ofthree structural domains: a lipid A region, a link region, and a repeating

carbohydrate side chain. The lipid A region is responsible for many biological responses
ranging from fever to bone resorption. The carbohydrate side chain serves as a potent
antigen and is responsible for serotype specificity [51 ]. There are many reports of

differing structures of different LPS species from various bacteria; however, the
variability in potency and activity of LPS is relatively small considering its vast array of
potent biological activities [51 ]. The major cellular receptor for LPS is CD 14, which is
present on monocytic cells and neutrophils [63]. There is also a soluble form of CD 14

receptor (sCD 14) that binds to endothelial cells [63]. LPS must bind to CD 14 and a LPS-

binding protein to form a complex. The mechanism by which LPS stimulates the cells
has not been fully established [64]. When this receptor is occupied, the secretion of pro-

inflammatory cytokines such as IL-1, TNF, IL-6, and PGE: occurs [51 ]. Several studies
have shown that LPS upregulates expression ofthe CD 14 gene in several kinds of cells

[65-67]. Amano et al. recently reported that LPS stimulates endogenous expression of
CD 14 in murine calvarial cells, and that CD 14 is strongly involved in LPS-stimulated
bone resorption in these cells [68]. Hence, they suggested a functional role of the CD 14
receptor in LPS-stimulated bone resorption.
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LPS has been shown to stimulate bone resorption in vitro [69-72]. LPS of oral
bacteria such as P. gingivalis. A. actinomycetemcomitans, and Prev. intermedia have

been implicated in the etiology and pathogenesis of periodontal disease because they can

provoke inflammatory and immune responses, and stimulate bone resorption. It has been

suggested that LPS can penetrate gingival connective tissue and induce a local
inflammatory response that leads to periodontal bone resorption [73]. A recent study by

Zubery et al, indicated that live or heat killed P. gingivalis stimulates similar bone
resorption in mice calvaria [50] and suggests that LPS plays an important role. LPS from
periodontopathic bacteria are potent inducers oflL-l[64, 74, 75]. Studies have shown
that LPS concentrations as low as 1 ng/ml can activate production, and amounts oflL-1
release have been reported as high as 100 ng/106 cells/24 hrs [76].

LPS can stimulate COX-2 expression directly or indirectly. The direct effects are
seen early after LPS treatment. Barrios-Rodiles and colleagues reported that LPS-

induction of COX-2 mRNA levels, in vitro, in human macrophages occurred as early as

2h, peaked at 6-12h and was maintained at high levels at 24 and 48h [77]. They also
stimulated macrophages at different times with LPS in the presence or absence of

neutralizing anti-IL-113 antibodies. Antibodies to IL-113 did not affect COX-2 mRNA
expression induced by LPS at early time points but inhibited the expression of COX-2

after 12h suggesting that the effect of LPS after 12h was mediated by LPS induced IL-1.

A recent in vivo study examined the effect of LPS on renal COX-2 expression in the rat

[78]. This study found that in cultured mouse renal medullary cells, LPS stimulated
COX-2 and CD 14 expression and the COX-2 expression was reduced by the addition of

13

CD 14 monoclonal antibody, suggesting that LPS stimulated the COX-2 expression
through a CD 14-dependent mechanism.

Prostaelandin Inhibitors

Nonsteroidal anti-inflammatory drugs (NSAIDS) replace arachidonic acid in the
active site of COX enzymes and prevent production of PGH2 and consequently

prostaglandins. NSAIDs inhibit prostaglandin production and are widely prescribed as
inhibitors of COX activity to control inflammation and pain. Conventional NSAIDS

such as aspirin and indomethacin, nonspecifically inhibit both COX-1 and COX-2 at
standard anti-inflammatory doses. The desirable anti-inflammatory and analgesic effects
occur through the inhibition of COX-2, but the undesirable effects of gastrointestinal

toxicity and bleeding occur as a result of COX-1 inhibition. Recent studies on the effects
of NSAIDS, specifically flurbiprofen and ibuprofen, on bone loss in periodomitis

revealed a decrease in alveolar bone loss in humans and beagles[79, 80]. The suppregsion
of PGE: with these drugs greatly diminishes attachment and bone loss and therefore
decreases periodontal disease progression. Other studies have demonstrated a decrease in
tooth movement in animal models treated with NSAIDs [5, 81 ]. Since COX-2 may be
the isoform that predominates at sites of inflammation, and COX-1 is responsible for the

"housekeeping" functions such as renal blood flow maintenance and gastric
cytoprotection, the development of specific COX-2 inhibitors may prove to be more
effective than nonspeeific NSAIDs in targeting inflammation such as periodomal disease.

One such COX-2 specific inhibitor is NS-398, which has recently been introduced.
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Futaki et al. reported preferential inhibitory effects ofNS-398 on COX-2 activity in rats

treated with LPS in vivo [82]. It has also proved to be more potent in inhibiting COX-2
in cultured rat bone cells [83]. A recent study by Shimizu et al. indicated that NS-398

completely inhibited PGE: synthesis from human PDL cells subjected to mechanical
tension force [4].

Hypothesis

We hypothesize that inflammatory agems will transcriptionally induce COX-2
gene expression in bone cells similarly in vivo and in vitro. Specifically, we propose that
the inflammatory agents lipopolysaccharide (LPS) and interleukin-1 (IL-1) will induce
COX-2 gene expression similarly in (1) freshly isolated calvariae, (2) cultured calvariae,

and (3) isolated primary calvarial cells.

Specific Aims

1) To measure COX-2 transcriptional regulation in freshly isolated calvariae from Pluc
mice treated in vivo with LPS. We will inject mice with lipopolysaccharide or vehicle

and sacrifice mice at varying times up to 8 h after injection. Calvariae will be dissected
out and half of each calvarium will be used for measurement of luciferase activity. The

other half calvarium will be used to obtain RNA for Northern analysis to determine if

COX-2 endogenous gene expression correlates with luciferase activity.

2) To measure COX-2 transcriptional regulation in cultured neonatal calvariae from Pluc
mice. Calvarial cultures will be treated with vehicle or LPS or IL-1 for varying times up
to 24 h and then extracted for luciferase activity. In some cases, calvariae will also be

extracted for RNA to determine endogenous gene expression. RIA to determine COX-2

activity will measure PGE2 accumulation in the culture media.
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3) To measure COX-2 transcriptional regulation in primary osteoblastic cells
enzymatically digested from Plue ealvariae. Cultured cells will be treated with varying
doses of LPS or 1I,-1 for varying lengths of time, and cells extracted for luciferase

activity. In some cases, RNA will be extracted to determine COX-2 endogenous gene
expression. RIA to determine COX-2 activity will measure PGE accumulation in the
culture media.

Materials and Methods

Materials: LPS from Escherichia coli, 055:B5, for cell culture experiments,

dexamethasone (DEX), and Dulbecco’s modified Eagle’s medium (DMEM) was

purchased from Sigma Chemicals Co., St. Louis, Mo. LPS from Escherichia coli,
026:B6, for tissues, was purchased from Difco Laboratories, Detroit, M/(4mg used for
30g mouse). IL-lt and IL-113 were purchased from Boehringer Manheim, Indianapolis,

Transgenic Mice: To further examine COX-2 transcriptional regulation in vivo, in organ

culture and isolated cells, transgenic mice were developed by the Transgenic Animal
Facility (UCHC). The mice used for this study were transgenic for -371/+70 bp of the
COX-2 5’-flanking regions fused to a luciferase reporter gene and developed in a CD-1

background. The term "transgenic" refers to the insertion of DNA from any source
directly into a mouse through a pronuclear injection technique. The production of
transgenic mice involves a specific sequence of events from DNA preparation to DNA
analysis by Southern blotting [84]. Once the DNA construct is isolated and purified, it is

ready for microinjection. Five-to six-week-old female mice are superovulated, mated to
fertile males, and then sacrificed. The DNA construct is microinjected into the

pronucleus of a one-cell mouse embryo. The surviving embryos are reimplanted into
pseudopregnant foster female mice. When the mice are 3-5 weeks old, they can be
screened for the transgenic construct through tail biopsy and DNA analysis by Southern
blotting. Mice used in this study are the result either of crossing a male Pluc mouse with
17
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a non-transgenic female mouse (heterozygous) or of crossing two Pluc mice

(homozygous). Because the integration site of the DNA construct can affect its
expression and regulation, we have developed 4 lines of mice from independently

microinjeeted pronuclei. For each type of experimem, we must confirm that the result is
not dependent on the integration site by doing the experiment in different transgenic

lines.

Cell Culture: All cells were cultured in phenol red free DMEM with 10% heatinactivated fetal calf serum, penicillin (100 U/ml) and streptomycin (50 ug/ml) at 37C in
a humidified atmosphere of 5% CO: in air.

PrimatT osteoblastic (POB) cells:

Calvariae were excised, dissected free of loose

connective tissue, washed with phosphate buffered saline (PBS) ph 7.4. and treated with

crude collagenase P (Boehringer Mannheim) and trypsin for 10 min at 37C. The

digestion procedure is repeated to provide five populations of cells. Released cells are

removed, and the reaction is stopped with DMEM and 10% FCS. We digested neonatal
calvariae from a single litter (n=2-8), pooled populations 2-5, and grew cells for 5-7 d to

confluence. Confluent cells were split, plated at 5000/cm: in 6-well dishes and cultured
for 7 d before treatment with LPS (101ag/ml), IL-1 (2ng/ml), 1 lxM dexamethasone, and 10

txM arachidonic acid.

Cultures were treated for varying time intervals up to 48 h.

Luciferase was extracted from n=3 wells for each treatment group and another 3 wells
were pooled for RNA extraction.
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Neonatal Calvarial Cultures: Calvarial cultures permitted us to use less agonist and

reduce mice discomfort. Cultured neonatal half-calvariae were treated with LPS (10

lxg/ml) and IL-1 (10ng/ml). The matched half calvariae were divided between vehicle

(control) and treatment groups. We used 6 half-calvaraie in each treatment group, 3 for
luciferase activity and 3 for RNA extraction. The induction of COX-2 has previously

been shown to be spontaneously induced in the first 24 h by culture in calvariae [85].

Hence, we pre-cultured bones for 24 h before treatment. The cultures were treated for
1.5, 3, 4, 6, 8 and 24 h. Each experiment was repeated 3 times and experiments were

repeated to compare responses in 3 different Pluc371 lines.

Freshll isolated tissues: Four to six-week old male Pluc371 mice were injected
subcutaneously with 4mg of LPS or vehicle. The mice were sacrificed 3-4 h aider
injection to assess the direct effects of LPS on luciferase activity. Four to six mice were

used in each treatment group; the experiments were repeated at least three times. Half of
each whole calvarium was taken to measure luciferase activity, and half for RNA
extraction. This protocol was repeated for Pluc lines from 3-4 different founders.

COX-2 Transcriptional Regulation and Luciferase Assay: The COX-2 gene expression is

regulated at the transcriptional level. A typical eukaryotic gene control region consists of
a promoter and regulatory sequences. The promoter is the DNA sequence where the

general transcription factors and the RNA polymerase assemble. The regulatory

sequences are bonding sites for gene regulatory proteins, which control the rate of
transcription initiation. These sequences can be located upstream, downstream, or even
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adjacent to the promoter, and they can act in combinations to control gene transcription.

One way to study the regulation ofthe promoter region is to fuse it to a reporter gene. A
reporter gene encodes a protein that can be easily detected by an enzyme assay or

cytological stain. When the recombinant DNA molecules are used to transfect different
types of mammalian cells, the level, timing and cell specificity ofthe reporter gene

production will reflect the action ofthe regulatory DNA sequences in the construct [86].

For the experiments in this study, we use the proximal -371/+70 bp of the 5’-flanking
region of the murine COX-2 gene fused to a lueiferase reporter gene (Pluc) (Figure 3).
The luciferase reporter encodes the firefly (Photinus pyralis) luciferase enzyme, which is

used to monitor transcriptional activity. The enzyme catalyzes a ehemiluminescent
reaction that produces a flash of light. The light production is measured using a

luciferase assay and luminometer. The-371/+70 bp ofthe 5’-flanldng region was chosen

because previous studies have shown that for most agonists studied, the major cis-acting
sites for induction ofluciferase activity lies between-150/+70 and -40/+70 bp [20, 21 ].

Previous studies in our lab examined transcriptional regulation of COX-2 expression in

MC3T3-E 1 cells stably transfected with COX-2 promoter-luciferase reporter (Pluc)
constructs. These studies showed that the stimulation of luciferase activity is associated

with the induction of COX-2 expression [ 10, 20, 87, 88].

(1) Cells. Luciferase activity was measured in soluble cell extracts prepared with
a kit from Promega (Madison, WI) using an automatic injection luminometer (Berthold

Lumat; Wallac Inc., Gaithersbury, MD). For each experiment, 3 wells of a 6-well dish of
cells were analyzed per treatment group. Cells were scraped in 200 l.tl of lysis buffer,

cemrifuged for 30 sec and supematants collected. 100 lal of substrate is injected into 10-
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20 I.tl of supematant and counts per second counted for 10 see. Activity was normalized
to total protein measured with a bicinchoninic acid (BCA) protein assay kit (Pierce;

Rockford, IL). Samples were mixed with BCA on a microtiter plate and incubated at
37C for 30 minutes. Absorbance was read at 562 nm with a microtiter plate reader

(Dynatech MR5000, Dynatech Laboratories) and the protein concemration ofthe samples
was determined.

(2) Tissues. Tissues were placed in 500 lxl of lysis buffer and polytroned for 2030 seconds. The extracts were centrifuged for 2 minutes and the supematants collected

and frozen overnight at-20C. The supematants were assayed the next day.

Northern Blot Analysis: Total RNA was extracted by the method of Chomczynski and
Sacehi [89]. Three 35mm wells of POBs cells and 3-6 half calvaraie were used. Cells or

tissues were washed with phosphate buffered saline (PBS) and homogenized in 4M
guanidinium thiocyanate (GTC) by polytron, extracted with phenol/chloroform-isoamyl

alcohol (241), and RNA precipitated with isopropanol and washed with 80% ethanol.
After quantitation at 260nm, 10-20 lag of total RNA was prepared with ethidium bromide
to run a gel. The samples oftotal RNA are run on a 1% agarose-2.2 M formaldehyde gel

and transferred to a nylon membrane by positive pressure. The RNA is fixed to the

membrane by UV irradiation using a Stratagene UV Stratalinker 1800. After 3 h of

prehybridization in a 50% formamide solution at 42C, filters were hybridized overnight
in a similar solution in rotating cylinders at the same temperature with the random primer

[3:p] dCTP-labeled cDNA probe.

Filters were washed once in a 1X SSC, 1% SDS

solution at room temperature, once in 0.1X SSC, 0.1% SDS solution at 65C, and then 4
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more times in the latter solution at room temperature. Alter washing, the filter was

exposed to Kodak XAR-5 film at -70C. Filters were hybridized sequentially with

cDNAs for COX-2, lueiferase (LUC), and a housekeeping gene, glyceraldehyde-3phosphate dehydrogenase (GAPDH). Filters were stripped with boiling 0.1% SDS and
0.1 X SSC between hybridizations. Signals were quantitated by densitometry.

Autoradiographs were scanned and analyzed using NIH Image sotare.

PGE_.Assays: Medium was removed from cultured calvariae or POB cells and PGE
accumulation was measured as described by Raisz and Simmons[90].

{3H}-

prostaglandins are used as a tracer and the assays run at antibody dilutions providing 20
to 40% binding. The lower detection limit of the assay for PGE: is approximately 5 pg

per tube or 0.14 nM in a

1001xl sample, and the intra assay variation was 6%. The assays

are carried out at 4 C and free prostaglandin removed with dextran-coated charcoal. The

values for unknowns were calculated from a standard curve using the logit-log, curve-

fitting computer program (simple RIA program, D. Rodbard, BCTIC, Computer Code
Collection, Nashville, TN). Data is presented as nM.

Statistical Analysis: Statistical significance of differences was determined by analysis of

the variance (ANOVA) with post-hoc comparison by the Bonferroni method or ANOVA

by Ranks.

Results

Effects ofLPS and IL-1 on COX-2 expression and luci[erase activit in cultured
calvariae from transgenic mice:

We have previously shown that COX-2 mRNA is not detectable in freshly
isolated ealvariae. However, COX-2 mRNA is rapidly and transiently induced on

culturing the calvariae [85]. Hence, we "pre-cultured" the calvariae for 24 h before
treatment with agonists to allow this initial induction to dissipate. Cultures were then

treated with vehicle or LPS (10 lxg/ml) for 0, 4, 6, 8. and 24 h. COX-2 mRNA levels
were determined by Northern analysis. COX-2 mRNA levels were increased at 4 h

compared to 0 h in vehicle treated cultures and gradually decreased thereafter (Fig 4).
LPS increased COX-2 mRNA levels relative to controls at 4, 6 and 8 h and levels
remained slightly elevated at 24 h. The peak effect of LPS was seen at 4 h.

In the same culture system, our lab has previously shown that IL-1 (10 ng/ml)
stimulated COX-2 mRNA expression in cultured neonatal mouse calvariae [ 14]. The

peak effect of IL-1 was at 4h and effects were maintained at 24 h.

To determine if the LPS induction of COX-2 rnRNA was transcriptionally
mediated, we measured luciferase activity in cultured calvafiae. Because there was a

possibility that the expression of the transgene would vary depending on the site of

chromosomal DNA incorporation, we compared LPS (10 lxg/ml)-stimulated luciferase
activity in calvariae from different lines oftransgenic mice. Because there was peak

expression of COX-2 mRNA levels at 4 h, we chose a time point of 6 h to allow for the
production of the functional luciferase enzyme. Table 1 shows a comparison of the mean
23
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luciferase activity, in counts per second (cps), normalized to total protein (tg), and foldincreases in four experiments. The basal Pluc activity was lowest in Line 157(1.0 + 0.1),

highest in Line 145(143.6 + 13.9) and intermediate in Line 143 (11.1 + 2.9, 13.2 + 2.7).

Although the basal levels of Lines 157 and 145 were markedly different, the foldincreases (treated/control ratio) with LPS treatment, 4.8 and 3.8 respectively, were
similar. Comparison of two experimems using Line 143 showed similar basal activities

but the fold-increases were 2.2 and 7.8. However, for Line 143, the LPS effect on
luciferase activity was not statistically significant in the experiment with the fold-increase

of 7.8. Including only the statistically significant results, the effect of LPS on luciferase
activity was 2-5 fold for all lines.

We also examined the IL-1 effects on luciferase activity in cultured calvariae
from two lines of transgenic mice at 6 h. Figure 5 compares the effects oflL-1 (2ng/ml)
and LPS (10 ug/ml). IL-1 increased the mean luciferase activity significantly by 2.6-fold

(Line 143) and 4.9-fold (Line 145) after 6h of treatment. This was similar to the foldincreases seen with LPS.

To determine if the medium PGE levels corresponded with the LPS and IL-1
stimulated luciferase activity, we measured PGE: production by RIA in the same

experiments shown in Fig 5. After 6 h, the basal (control) levels of PGE: were similar
for lines 143 (6.7 + 1.2 nM) and 145 (7.0 + 2.1 nM) (Table 2). The levels were much

higher after treatment with LPS. There was a 6.2 fold-increase in Line 143 and a 15.1
fold-increase in Line 145 (Table 3).

The LPS-stimulated increase in PGE: production was 3-4 fold greater than the

LPS- stimulated increase in Pluc activity. This discrepancy between luciferase activity
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and PGE2 production suggests that LPS regulates COX-2 through other promoter regions

than in our Pluc construct or that LPS regulates arachidonate availability.

There were fewer differences seen with IL-1 treatment in the same experiment. In
Lines 143 and 145, IL-1 stimulated both Pluc activity and PGE: production 3-5 fold,

indicating that the PGE: response to IL-1 is largely the result of transcriptional induction
of COX-2 via the-371/+ 70 bp flanking region.

Effects of dexamethasone (Dex) on cultured calvariae from transgenic mice:
To determine the effect of dexamethasone (Dex) on endogenous expression of

COX-2, we treated cultured neonatal mice calvariae (Line 145) with vehicle (control), IL1 (2 ng/ml), Dex (10-6M), and Dex + IL-1 for 6 h. In this experiment, we saw expression

of COX-2 mRNA in control cultures after 6 h (Fig 6). The COX-2 mRNA level was
increased after IL-1 treatment. Dex inhibited COX-2 mRNA expression in both control

cultures and IL-1 treated cultures. With Dex + IL-1 treated calvariae, COX-2 expression
was detectable, but to a much less extent than in IL-1-treated and control cultures.

We also examined luciferase activity in the same experiment as shown in Figure 6
to determine the effect of Dex. After 6 h, control levels of mean luciferase activity were

4.4 + 0.8 cps/l.tg protein. There was an increase atter IL- 1 treatment (198.7 + 131.5

cps/l.tg protein) (Fig 7). Because there was a large SEM for the IL-1 treated cultures,
there was no statistically significant effect oflL-1. Luciferase activity in Dex and Dex +
IL-1 cultures was 32.4 + 9.1 cps/l.tg protein and 42.1 + 23.2 cps/l.tg protein, respectively,

suggesting that Dex inhibited IL-1 stimulated luciferase activity. We also measured the
medium PGE: levels in this experiment. Control and IL-1 cultures had PGE: levels of
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58.6 + 23.2 nM and 84.1 + 51.5 nM, respectively. The IL-1 treated groups had a high

SEM in and therefore; the differences from control were not significant. The levels for
the Dex and Dex + IL-1 groups were 10.6 + 0.8 nM and 22.7 + 7.6 nM, respectively.

Due to the large SEM, we repeated this experiment in a different line (Line 157) and
measured luciferase activity at 6h (Fig 8). Although the trend for an increase in
luciferase activity in IL-1 treated cultures and a decrease in luciferase activity in Dex +
IL-1 treated cultures was the same as seen in the previous experiment, the differences
were not statistically significant.

Effects ofLPS and 1L-1 on luciferase activi in primary osteoblastic cells derived from
transgenic mice:

To compare the LPS and IL-1 induction of COX-2 expression in cultured calvaria
and primary osteoblastic cells, we measured luciferase activity in primary osteoblastic

cells derived from neonatal transgenic mouse calvariae. Figure 9 shows a comparison of

effects of the IL-1 and LPS on luciferase activity in primary osteoblastic cells from Line
157. Cells were treated with vehicle (Control), LPS (10 l.tg/ml) and IL-1 (2 ng/ml) for 0,

3, 4.5, 6, 7.5, and 24 h. Peak expression of luciferase activity was seen between 4.5- 6
hours for both LPS and IL-1 treated cells. Table 4 shows a comparison of the mean
luciferase activity, in counts per second (cps), normalized to total protein (ktg), and foldincreases in six experiments. The cells were treated with vehicle (control) or LPS (10

l.tg/ml) for 6 h. Basal activities for the four different lines ranged from 6.0 to 30.5 cps/l.tg
protein, except for one experiment with line 157 where the basal activity was 305.4

cps/tg protein. Despite differences in the basal activities, LPS stimulated a 2 to 4 fold-
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increase in luciferase activity for all lines. We also compared IL-1 (2 ng/ml)- stimulated
luciferase activity in primary osteoblastic cells derived from neonatal transgenic mice
calvariae (Table 4). IL-1 induced lueiferase activity significantly by 2-4 fold for all
lines. Both IL-1 and LPS had similar effects on luciferase activity in primary osteoblastic

cells and cultured calvariae from transgenic mice.

In another experiment, we measured medium PGE: levels (nM) to determine if
prostaglandin production corresponded with lueiferase activity (cps/lxg protein) in
primary osteoblastic cells derived from transgenic mice ealvariae (Line 157) (Fig 10).

Cens were treated with vehicle, LPS (10 lxg/ml), or IL-1 (2 ng/na) for 6 h, with and
without arachidonate (AA) (10 -5 M). The arachidonate was added to provide excess

substrate for COX, allowing maximal COX (both COX-1 and COX-2) activity to be
determined. LPS increased luciferase activity 2.3 fold (treated/control) both without AA

and with AA at 6 hours. IL-1 induced luciferase activity 4.1 fold without AA and 3.2

fold with AA. At 6 h, the medium PGE: in control cultures was 3.9 nM and 6.4 nM
without and with AA, respectively. LPS increased PGE: levels by 2.5 fold without AA

and 9.5 fold with AA. IL-1-stimulated PGE: production exhibited similar fold-increases
both with and without AA, (2.0 and 2.8 fold, respectively). Hence, for IL-1, the maximal
increase in PGE: concentration obtained in the presence of AA to provide excess

substrate, correlated with the increase in luciferase activity. For LPS, however, the
maximal increase in PGE concentration was 3x greater than the increase in luciferase

activity.

We also conducted an experiment using indomethacin (lndo) to determine if

endogenously produced PGs mediated some of the increase in Pluc activity stimulated by
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LPS in Line 145 (Fig 11). In this experiment, primary osteoblastic cells were treated
with vehicle (control), LPS (10 lag/ml), Indo (10 -6 M) or Indo + LPS for 6 h. LPS

significantly increased Pluc activity to 73.3 + 6.5 and 119.5 + 7.7 cps/l.tg protein, without
and with Indo, respectively. Hence, Indo did not decrease LPS- stimulated Pluc activity.

Effects ofLPS on COX-2 Expression rout luciferase activity m freshly isolated tissues
from transgenic mice:
COX-2 mRNA levels were determined by Northern analysis in freshly isolated
calvariae from an 11.5 week old transgenic mouse (Line 145) (Fig. 12). The mouse was

injected with 4mg of LPS or with vehicle, and sacrificed after 3.5 h. Expression of COX2 mRNA and luciferase (Luc) mRNA was not detectable in vehicle treated mice. Both

COX-2 mRNA and Luc mRNA levels were highly detectable after 3.5 h in the LPS
treated mice.

In another experiment and different line (Line 128), LPS induced COX-2
expression in one half of freshly isolated mouse calvaria after 3.5 h (Fig. 13). Again,

LPS markedly increased COX-2 mRNA levels relative to control.

To determine if the LPS induction of COX-2 mRNA was transcriptionally
mediated in vivo, we measured luciferase activity in the other half of the freshly isolated

calvariae used for RNA in the experiment shown in Fig 13. Figure 14 shows measured
luciferase activity in counts per second (cps), normalized to total protein (l.tg). LPS

increased luciferase activity from 128 to 863 cps/l.tg protein after 3.5 h, in an increase of

7-fold. The COX-2 mRNA was induced to 2.6 with LPS treatment. Hence, there was an
induction of COX-2 mRNA and luciferase activity in vivo as seen in vitro.
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We also examined LPS-stimulated fold increases (treated/ntol) in luciferase
activity (cps/I.tg protein) for different freshly isolated tissues. Figure 15 illustrates the
varying fold-increases of several tissues from 3-5 independent experiments. Calvarial

bone had the highest expression of lueiferase activity upon LPS stimulation, exhibiting a
20- fold increase. Lung, kidney, heart and colon had 5-12- fold increases and brain had

the lowest fold-increase in lueiferase activity (2-fold).

Discussion

Many previous studies of COX-2 transcriptional regulation have used lonal
MC3T3-E 1 cells, an immortalized osteoblastic cell line derived from murine calvariae

that were transfected with the COX-2 promoter-luciferase reporter (Pluc) construct [20,

87, 91 ]. The use of immortalized osteoblasts for studying transcriptional regulation has
been criticized as not being representative of more ’normal’ osteoblastic cells. Also,
Krebsbach et al. found differences in COL1A1 promoter activity between primary bone
cells and cultured calvariae from neonatal transgenic mice, suggesting that regulation was

changed by taking ceils out of their norm matrix environment [92]. Hence, the
rationale for using the different systems such as cultured ealvariae, primary osteoblastic

cells, and in vivo tissues is to (1) compare the COX-2 transcriptional regulation in
’normal’ osteoblasts from mice transgenic for the Pluc constructs with previous results

from MC3T3-E 1 cells, and (2) to compare regulation in bone tissue with regulation in
bone cells. In vivo studies require large number of mice and agonists and cause mice
discomfort. Therefore, if in vivo regulation is similar to that seen with primary

osteoblasts, then this latter model would be used for further transcriptional studies. We
wanted to examine the effects of the inflammatory agems, IL-1 and LPS, on COX-2
regulation. Because in vivo injections of IL-1 are costly, we chose to use LPS for in vivo
studies.

Overall, we found the regulation of COX-2 expression and Pluc activity in
cultured neonatal calvariae, primary osteoblastic cells, and in vivo mice experimems to
be similar. COX-2 mRNA levels were low or undetectable on Northern analysis under
30
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unstimulated conditions. However, luciferase activity was measureable under the same
conditions. This may be attributed to the fact that COX-2 is continuously being
transcribed and rapidly degraded such that it is low or undetectable on the Northern

analysis.

LPS induced COX-2 mRNA expression similarly for both cultured and freshly
isolated calvariae after 3.5-4 h. Northern analysis of cultured calvariae revealed a
transient expression of COX-2 rnRNA with peak expression at 4 h and decreasing levels

by 24 h. LPS induced Pluc activity similarly (2-5 fold) in vitro for different lines of
cultured calvariae and primary osteoblastic cells with a peak response at 6 h. Peak
expression in luciferase activity was seen two hours later than the COX-2 mRNA
expression possibly because ofthe time needed to allow for the production of the
luciferase enzyme.
IL-1 had similar effects on both Pluc activity and COX-2 mRNA expression in

cultured calvariae. For both cultured calvariae and primary osteoblastic cells, the 1L-1
induction ofPluc activity was 2-5 fold, which parallels the treatment with LPS.

Moreover, the IL-1 induction of COX-2 rnRNA and of luciferase activity in primary
osteoblast cells paralleled the induction in MC3T3-E 1 cells seen in previous studies [20]

To determine if the changes in PGE: production could be largely explained by
transcriptional induction of COX-2, we measured PGE: levels in the medium of calvarial
cultures and compared them with Pluc activity. In primary osteoblastic cells, IL-1
stimulated Pluc activity by 3-4 fold and increased PGE: by 2-3 fold. The similar increase
in Pluc activity and PGE: production with IL-1 suggests that most of the IL-1 stimulated

PGE: production occurs via IL-1 inducing new COX-2 gene expression.
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In calvarial cultures, the PGE: production stimulated by LPS was 3-4 times
greater than luciferase activity stimulated by LPS. This could be explained by the fact

that LPS increased arachidonate availability or that promoter regions (putative sites)
other than those in the Pluc construct are involved. We added excess arachidonate to

osteoblast cultures so that substrated release would not be limiting. Nevertheless, LPS
stimulated PGE: production was 3-fold greater than LPS stimulated luciferase activity. It
is possible that LPS increases COX-1 activity, although we did not see an increase in

COX-1 mRNA with LPS (data not shown). It is also possible that regions of the COX-2
promoter not in our-371/+70 bp construct mediate some ofthe effects of LPS, and we
can assess this possibility by studying larger promoter constructs.

Glucocorticoids such as cortisol and dexamethasone have been shown to inhibit
the IL-1 or LPS- induction of COX-2 in various cells including human monocytes,

macrophages, and cultured mouse calvarial cells [ 14, 93, 94]. We found that
dexamethasone (10 -6 M) inhibited the IL-1 induction of COX-2 mRNA. Although the
data suggested that dexamethasone also inhibited luciferase activity and PGE:
production, the differences were not statistically significant. Therefore, we can not

conclude that effects of dexamethasone on COX-2 are transcriptional. Although we did
not measure the effects of dexamethasone on COX-2 in vivo, further investigation in vivo

would be necessary to determine if the LPS and IL-l-induction of COX-2 activity is
inhibited by dexamethasone similarly in vitro and in vivo.

In in vivo studies, the LPS-stimulated COX-2 mRNA expression correlated with
Pluc activity for calvarial bone suggesting that similar regulation of COX-2 and Pluc

occurred in vivo and in vitro. Preliminary studies in our lab found that mouse calvarial
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bone was among the tissues that most highly expressed COX-2 after LPS (4mg) injection.
The other tissues compared were heart, lung, colon, spleen, kidney, liver and brain. The

lowest fold induction of luciferase activity was seen in brain; however, this did not
correlate with the Northern analysis in which there was a marked increase in LPSstimulated COX-2 mRNA expression (data not shown). One possible explanation for this

discrepancy is that there are missing regions from the-371/+70 bp COX-2 promoter
resulting in decreased induction ofthe transgene. It is also possible that LPS may be
regulating post-transcriptional regulation of COX-2 rnRNA which may increase COX-2

mRNA expression.

We found a great deal of variability in luciferase activity stimulated by LPS for
the tissues studied in vivo. Comparison of the same tissue from different mice could vary
because of different rates of LPS metabolism in different mice, differences in injection
times or sites, and differences in the exact location of tissues sampled. In addition, there

may be differences between the chromosomal imegration sites of mice affecting the

regulation of the Pluc construct but we did not see large differences in our in vitro studies
of calvariae and osteoblastic cells.

In summary, our study suggests that in calvarial cultures and freshly isolated
calvariae, the LPS induction of luciferase activity paralleled the LPS induction of COX-2

mRNA. IL-1 (2ng/ml) and LPS (10 tg/ml) stimulated luciferase activity similarly in
calvarial and primary osteoblastic cell cultures. Furthermore, IL-1 increased both PGE2

production and luciferase activity similarly. LPS increased PGE: production more than
luciferase activity. We can conclude that the COX-2 response to IL-1 is largely due to
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transcriptional induction via the-371/+70 bp region of the COX-2 promoter. The
maximal response to LPS may require additional regions of the COX-2 promoter.

Tables
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Figures

Figure 1- Pathway of prostaglandin production. Arachidonic acid is released from

cellular membranes by regulated phospholipases, converted to PGH: via COX, and then

PGH: is converted to PGs by individual PG synthases. The two COX isoforms, COX-1
and COX-2, are approximately 60% identical at nucleic and amino acid levels.
Figure 2- Contact-dependent interaction between hematopoietic osteoclast progenitors

and osteoblasts or other stromal cells for the formation of mature osteoclasts. The
interaction of RANK with RANK ligand is required for differentiation into mature, bone-

resorbing cells.
Figure 3: The COX-2 promoter-luciferase reporter construct (Pluc). The -371/+70bp of
5’ flanking region of the COX-2 promoter was fused to a luciferase reporter gene.
Figure 4: Lipopolysaccharide (LPS) induction of COX-2 mRNA levels in cultured

calvariae from transgenic mice (Line 143). Cultures were treated with vehicle or LPS (10

lxg/ml) for times indicated. RNA was extracted and Northern analysis was performed as
described in Materials and Methods.

Figure 5: Comparison of IL-1 and LPS-stimulated luciferase activity in cultured
calvariae from two lines of transgenic mice. Luciferase activity, in counts per second

(cps), was normalized to total protein. Cultures were treated with vehicle (Control), LPS

(10 t,tg/ml) or IL-1 (2ng/ml) for 6 h. Fold activity was calculated as treated/control ratios.
Data are means + SEM for 3-4 wells. *Significantly different from control, p < 0.01.
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Figure 6: Inhibition of COX-2 mRNA expression by dexamethasone (DEX, 10.6 M) in

cultured calvadae (Line145). Cultures were treated for 6 h. RNA was extracted and
Northern analysis was performed.
Figure 7: Comparison of luciferase activity and PGE2 levels in cultured calvariae from
Line 145. Cultures were treated with vehicle (Con), IL-1 (2ng/ml), Dex (10 -6 M) or Dex

+ IL-1 for 6 h. Luciferase activity, in counts per second (cps) was normalized to total
protein. PGE2 concemration was calculated as nM. Bars are means + SEM for 3
measurements.

Figure $: Luciferase activity (cps/tg protein) in cultured calvariae from Line 157.

Cultures were treated with vehicle (Con), IL-1 (2 ng/ml), Dex (10 -6 M) or Dex + IL-1 for
6 h. Bars are means + SEM for 4-5 measurements.

Figure 9: Comparison of luciferase activity (cps/l.tg protein) in primary osteoblastic cells

from Line 157. Cells were treated with vehicle (Control), LPS (10 l.tg/ml), or IL-1 (2

ng/ml) for 0, 3, 4.5, 6, 7.5, and 24 h. Peak expression was seen between 4.5-6 h. Data
are means + SEM for 3 measurements.

Figure 10: Comparison of luciferase activity and PGE: concentration in primary
osteoblastic cells derived from neonatal transgenic mice ealvariae. Cells were treated
with vehicle (Con), LPS (101.tg/ml) or IL-1 (2 ng/ml) for 6 h with and without
arachidonate (10 -5 M).

PGE: levels were measured by RIA. Numbers above bars

indicate fold-increases (treated/control ratios). Bars are means + SEM for 3-6
measurements. * Significantly differems from control, p < 0.05 as determined by

ANOVA. ** Significantly different from control, p < 0.05 as determined by ANOVA on

42

Figure 11- Comparison of luciferase activity (cps/ktg protein) in primary osteoblastic

cells from Line 145. Cells were treated with vehicle (Control), LPS (10 tg/ml), Indo

( 10 -6 M) or Indo + LPS for 6 h. Bars are means + SEM for 3-6 measurements.
Figure 12- Northern analysis of COX-2 mRNA and Luciferase (Luc) mRNA levels in

freshly isolated calvaria from an 11.5 week old transgenic mouse (Line 145). The mouse
was injected in vivo with vehicle (-) or 4 mg of LPS (+) and sacrificed 3.5 h after

injection.
Figure 13: Nonhero analysis of COX-2 mRNA levels in fleshly isolated calvariae from

transgenic mice (Line 128). Mice were injected in vivo with vehicle (-) or 4 mg of LPS

(+). Mice were sacrificed 3.5 h after injection. GAPDH mRNA and 18 S and 28 S
ribosomal RNA on gel are shown to assess RNA loading.

Figure 14: Comparison of COX-2 mRNA normalized to GAPDH mRNA and lueiferase

activity in fleshly isolated calvariae from transgenic mice (Line 128). Mice were injected
in vivo with vehicle or 4 mg of LPS. Mice were sacrificed 3.5 h after injection.

Figure 15: Comparison of LPS- stimulated fold-increase in luciferase activity in
different tissues. Mice were injected in vivo with vehicle or 4 mg of LPS and sacrificed
3-4 h later. Bars are means _+ SEM from 3-5 independent experimems.
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